Rebekka Finger
Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis
Oct 1, 2017Multi centre, prospective, randomized, double blind, 2 treatment, 2 period crossover study with two 12-week treatment periods separated by a 4 week drug-free washout period and a 4 week follow-up performed at the University Hospital Berne, Basel, Zür...
Clinical Studies - Oct 1, 2017 - Dec 1, 2018
Automatically Closed
Project leader: Brutsche Martin
Members: Finger Rebekka, Tschirren Ursina, Baty Florent, Widmer Sandra
Kalydeco
Sep 1, 2015
Clinical Studies - Sep 1, 2015 - Sep 1, 2017
Automatically Closed
Project leader: Schoch Otto
Members: Finger Rebekka, Brutsche Martin, Kapfer Sarah, Schlotter Sandra
Tobramycin
Jul 1, 2014An open-label, crossover, interventional Phase IV study to compare the ease of use of tobramycin inhalation solution and nebulized colistimethate for the treatment of pulmonary Pseudomonas aeruginosa in patients with CF
Clinical Studies - Jul 1, 2014 - Mar 18, 2015
Completed
Project leader: Brutsche Martin
Members: Finger Rebekka
RAINIER
Aug 1, 2013Randomisierte, doppelblinde, placebokontrollierte, multizentrische Phase-II-Studie zur Bestimmung der Wirksamkeit und der Sicherheit von GS-6624 bei Patienten mit idiopathischer Lungenfibrose
Clinical Studies - Aug 1, 2013 - Aug 1, 2015
Completed
Project leader: Pellet Sarah
Members: Finger Rebekka, Brutsche Martin, Burger Barbara
Offene, nicht kontrollierte, multizentrische Phase IIIb Studie zur Beurteilung von Riociguat (BAY 63-2521) bei Patienten mit Chronisch Thromboembolischer Pulmonaler Hypertonie (CTEPH)
Jun 1, 2013Objective 1) To assess safety and tolerability, clinical effects of riociguat. 2) To provide access to riociguat for patients with in-operable chronic thromboembolic pulmonary hypertension (CTEPH), or recurrent or persisting pulmonary hypertension (P...
Clinical Studies - Jun 1, 2013 - Jun 1, 2015
Aborted
Project leader: Brutsche Martin
Members: Pellet Sarah, Finger Rebekka
A multicenter, reandomized, double-blind, single-dose study to assess the effect of the combined inhalation of 150 ug indacaterol maleate (QAB149) and 50 ug glycopyrronium bromide (NVA237) versus inhaled 150 ug indacaterol maleate (QAB149) alone on inspiratory capacity in patients with moderate or severe COPD
Oct 1, 2012A multicenter, reandomized, double-blind, single-dose study to assess the effect of the combined inhalation of 150 ug indacaterol maleate (QAB149) and 50 ug glycopyrronium bromide (NVA237) versus inhaled 150 ug indacaterol maleate (QAB149) alone on i...
Clinical Studies - Oct 1, 2012 - Aug 31, 2013
Completed
Project leader: Pellet Sarah
Members: Brutsche Martin, Finger Rebekka, Burger Barbara